

CONTENTS

Brief Correspondence	Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up	43
	<i>R. Bergroth, M. Matikainen, A. Rannikko</i>	
	External Validation of Two Nomograms Developed for ⁶⁸Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer ¹⁸F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible?	47
	<i>H.B. Luiting, S. Remmers, D. Meijer, A.N. Vis, M. Donswijk, D.E. Oprea-Lager, L. Emmett, I. Rauscher, H.G. Van der Poel, M.J. Roobol, P.J. van Leeuwen</i>	
Original Articles	Clinical Utility of Negative Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer and Clinically Significant Prostate Cancer	9
Prostate Cancer	<i>V.G. Wagaskar, M. Levy, P. Ratnani, K. Moody, M. Garcia, A.M. Pedraza, S. Parekh, K. Pandav, B. Shukla, S. Prasad, S. Sobotka, K. Haines 3rd, S. Punnen, P. Wiklund, A. Tewari</i>	
	Men with negative magnetic resonance imaging (MRI) findings pose a diagnostic challenge to physicians as they may have prostate cancer in the absence of accepted clinical predictors. Our model for selection of men with negative MRI findings for biopsy safely reduces the number of men who need to undergo a biopsy procedure.	
	Reassessment of Prostate Biopsy Specimens for Patients Referred for Robot-assisted Radical Prostatectomy Rarely Influences Surgical Planning	36
	<i>R.J. Hoekstra, W.J.H. Goossens, A. Beulens, H. van Herk, B.M. Hoevenaars, J. de Baaij, D.M. Somford, J.P.M. Sedelaar, J.-P.A. van Basten, H.J.E.J. Vrijhof</i>	
	Reassessment of prostate biopsy specimens taken in another hospital rarely leads to a change in surgical plan regarding the indication for a nerve-sparing approach and extended pelvic lymph node dissection. Therefore, reassessment of prostate biopsy specimens before radical prostatectomy can be omitted.	
	Estretol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)	52
	<i>H.J.T. Coelingh Bennink, J.A. van Moorselaar, E.D. Crawford, E.P.M. Roos, D.M. Somford, T.A. Roeleveld, T.D. de Haan, H.H.E. van Melick, Y. Reisman, Y. Zimmerman, G. van Osta, J. Krijgh, N.D. Shore, F. Saad, A.V. Schally, F.M.J. Debruyne</i>	
	Androgen-deprivation therapy (ADT) for prostate cancer with luteinizing hormone-releasing hormone (LHRH) agonists can be improved. Cotreatment of ADT with high-dose estretol in advanced prostate cancer patients results in fewer occurrences of hot flushes, bone protection, and other antitumor benefits.	
Bladder Cancer	Morbidity and Days Alive and Out of Hospital Within 90 Days Following Radical Cystectomy for Bladder Cancer	1
	<i>S.L. Maibom, M.A. Røder, A.M. Poulsen, P.O. Thind, M.L. Salling, L.N. Salling, H. Kehlet, K. Brasso, U.N. Joensen</i>	
	Radical cystectomy (RC) is associated with significant short-term morbidity. Days alive and out of hospital (DAOH) is a novel outcome measure of recovery after surgery. In this study, we find that that DAOH is a good marker of cumulative morbidity after RC.	

Pediatric Urology

**CDH12 as a Candidate Gene for Kidney Injury in Posterior Urethral Valve Cases: A Genome-wide Association Study Among Patients with Obstructive Uropathies**

26

L.F.M. van der Zanden, I.A.L.M. van Rooij, J.S.L.T. Quaedackers, R.J.M. Nijman, M. Steffens, L.L.L. de Wall, E.M.H.F. Bongers, F. Schaefer, M. Kirchner, R. Behnisch, A.K. Bayazit, S. Caliskan, L. Obrycki, G. Montini, A. Duzova, M. Wuttke, R. Jennings, N.A. Hanley, N.J. Milmoie, P.J.D. Winyard, K.Y. Renkema, M.F. Schreuder, N. Roeleveld, W.F.J. Feitz

We found that variants of CDH12 increase the risk of kidney injury in patients with posterior urethral valves. This is the first time that this gene has been reported on in this context. Our study provides interesting new information about pathways involved in obstructive uropathies and important leads for further research.

Surgery in Motion:
Open Science**Photodynamic Diagnosis-guided Dual Laser Ablation for Upper Urinary Tract Carcinoma: Preoperative Preparation, Surgical Technique, and Clinical Outcomes**

17

T. Yoshida, T. Murota, T. Matsuzaki, K. Nakao, C. Ohe, T. Matsuda, H. Kinoshita